Comparative study of the CYP2C19, CYP2C9, CYP4F2 gene polymorphisms impact on the clinical and laboratory characteristics of acute coronary syndrome patients-Reference-Cited by-同舟云学术

Comparative study of the CYP2C19, CYP2C9, CYP4F2 gene polymorphisms impact on the clinical and laboratory characteristics of acute coronary syndrome patients

Published:2023-07-19 Issue:1 Volume: Page:46-55
ISSN:2588-0527
Container-title:Pharmacogenetics and Pharmacogenomics
language:
Short-container-title:Fgen_Fgenom

Author:

Kantemirova B. I.¹^ORCID,Abdullaev M. A.¹^ORCID,Chernysheva E. N.¹^ORCID,Kitiashvili I. Z.²^ORCID,Zharkov Z. V.¹^ORCID,Romanova A. N.¹^ORCID,Konovalova E. R.³^ORCID

Affiliation:

1. Astrakhan state medical university

2. Russian Medical Academy of Continuous Professional Education

3. A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Abstract

Coronary heart disease (CHD) is one of the most common causes of death worldwide. The pharmacokinetic properties of drugs used to treat coronary heart disease depend on genetic factors, including the genotype of CYP2C19, CYP2C9 and CYP4F2. However, existing studies of the genetic basis of the response to treatment in patients with acute coronary syndrome (ACS) have contradictory results, requiring a more detailed study. Goal. In this study, we studied the distribution of the genotypes of CYP2C19*2, CYP2C9*2 and CYP4F2*3 among 59 patients diagnosed with ACS who received dual antiplatelet therapy. Methods. The polymerase chain reaction (PCR) method was used to determine the genotypes of CYP2C19, CYP2C9 and CYP4F2. A correlation analysis of the results of genotype carriage and clinical and laboratory parameters of patients was carried out. Results. The distribution of CYP2C9*2 genotypes was as follows: wild genotype (CC) was found with a frequency of 78 % (45 patients), heterozygotes (CT) — 22 % (12 patients), homozygotes (TT) were not detected. The CYP4F2*3 genotype was distributed as follows: 56.14 % (32 patients) had a wild genotype (CC), 31.5 % (18 patients) were heterozygotes with reduced enzyme activity (CT), 12.36 % (7 patients) were homozygotes for the T (TT) allele. The distribution of alleles and genotypes of CYP2C9 did not correspond to the Hardy-Weinberg equation (χ2 = 21.55; p = 0.044), while the distribution of alleles and genotypes of CYP4F2 corresponded to it (χ2 = 3.61; p = 0.0574). Conclusion. The study showed a high prevalence of the genotypes CYP2C9*2 (CT) and CYP4F2*3 (CT and TT) among patients with acute coronary syndrome. The carriage of CYP2C19*2 was significantly associated with adverse cardiovascular events in patients. These results suggest that genetic testing can provide valuable information for risk stratification and personalized treatment of patients with acute coronary syndrome

Publisher

Publishing House OKI

Subject

General Medicine

Reference26 articles.

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016 Jan 26;133(4):e38–60. DOI: 10.1161/CIR.0000000000000350.

2. Giacoppo D, Matsuda Y, Fovino LN, et al. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with secondgeneration drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. European heartjournal. 2021 Jan 21;42(4):308–19. DOI: 10.1093/eurheartj/ehaa739

3. Bhatt DL, Hulot JS, Moliterno DJ, Harrington RA. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12):1929–1943. DOI:10.1161/circresaha.114.302737.

4. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacologicalreviews. 2013 Jul 1;65(3):987–1009. DOI: 10.1124/pr.112.007252.

5. Fedina L.V., Mirzaev K.B., Sychev D.A., i dr. Vliyanie nositel'stva klinicheski znachimykh allel'nykh variantov genov CES1, PON1, ABCG2, CYP4F2, CYP3A4, IGTB3, P2Y12, PEAR1, B4GALT2 na antiagregantnoe deistvie klopidogrela i klinicheskie iskhody patsientov s OKS i fibrillyatsiei predserdii. Farmakogenetika i farmakogenomika. 2021;(2):19–20. [Fedina LV, Mirzoev KB, SychevDA, et al. The effect of carrying clinically significant allelic variants of the CS 1,PON1, ABCG2, CYP4F2, CYP3A4, IGTB3, P2Y12, PEAR 1, B4GALT2 genes on the antiplatelet effect of clopidogrel and clinical outcomes of patients with ACS and atrial fibrillation. Farmakogenetika i farmakogenomika = Pharmacogenetics and pharmacogenomics. 2021;(2):19–20. (In Russ.)]. DOI: 10.37489/2588-0527-2020-2-19-20.